Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H12I3NO4 |
Molecular Weight | 650.9735 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C(O)=O
InChI
InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
Molecular Formula | C15H12I3NO4 |
Molecular Weight | 650.9735 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1860 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Diagnostic | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
346 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
342 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
404 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4370 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4740 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4926 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12929 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13938 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Disc. AE: Anxiety, Palpitations... AEs leading to discontinuation/dose reduction: Anxiety (severe) Sources: Page: p.2Palpitations Agitation Shortness of breath Irritability Tachycardia Tremor |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.2Vomiting Abdominal pain Headache (severe) Confusion Disorientation Diplopia |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
DLT: Anxiety, Tachycardia... Dose limiting toxicities: Anxiety (50%) Sources: Page: p.3Tachycardia (50%) Loose stools (100%) |
37.5 ug 2 times / day multiple, oral MTD Dose: 37.5 ug, 2 times / day Route: oral Route: multiple Dose: 37.5 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 4 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 4 Sources: Page: p.3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Irritability | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Palpitations | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Shortness of breath | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tachycardia | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tremor | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Anxiety | severe Disc. AE |
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Abdominal pain | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Confusion | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Diplopia | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disorientation | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Nausea | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Vomiting | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Headache | severe Disc. AE |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Loose stools | 100% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Anxiety | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Tachycardia | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
PubMed
Title | Date | PubMed |
---|---|---|
The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. | 1998 Nov |
|
Arachidonic acid and PGE2 regulation of hepatic lipogenic gene expression. | 1999 Jun |
|
Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat. | 1999 Mar |
|
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells. | 2000 Feb |
|
Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. | 2000 Sep 22 |
|
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome. | 2001 |
|
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs. | 2001 Apr |
|
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions. | 2001 Apr |
|
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. | 2001 Apr |
|
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air. | 2001 Apr |
|
Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention. | 2001 Apr 6 |
|
[Diabetes mellitus caused by pancreatitis in a bull]. | 2001 Feb |
|
Differential in vitro suppressive effects of steroids on leukocyte phagocytosis in two teleosts, tilapia and common carp. | 2001 Feb |
|
Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. | 2001 Feb |
|
Effect of hypothyroidism on pathways for iodothyronine and tryptophan uptake into rat adipocytes. | 2001 Feb |
|
Regulation of mucin gene expression in human tracheobronchial epithelial cells by thyroid hormone. | 2001 Feb 1 |
|
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism. | 2001 Feb 15 |
|
Thyroid hormone and the cardiovascular system. | 2001 Feb 15 |
|
What is the optimal treatment for hypothyroidism? | 2001 Feb 5 |
|
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis. | 2001 Jan |
|
[Diagnosis of hyperthyroidism]. | 2001 Jan |
|
Endogenous depression, thyroid function and acupuncture. | 2001 Jan |
|
Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. | 2001 Jan |
|
Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. | 2001 Jan |
|
Subclinical thyrotoxicosis. | 2001 Jan |
|
Structure and expression of the transthyretin gene in the choroid plexus: a model for the study of the mechanism of evolution. | 2001 Jan 1 |
|
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo. | 2001 Jun 8 |
|
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis. | 2001 Mar |
|
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus). | 2001 Mar |
|
Perioperative considerations in a hypothyroid infant with hepatic haemangioma. | 2001 Mar |
|
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism. | 2001 Mar |
|
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. | 2001 Mar |
|
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. | 2001 Mar |
|
Homogeneous enzyme immunoassay for triiodothyronine in serum. | 2001 Mar |
|
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression. | 2001 Mar |
|
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression. | 2001 Mar |
|
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. | 2001 Mar 6 |
|
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle. | 2006 Mar |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1606687
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:28:11 UTC 2022
by
admin
on
Fri Dec 16 17:28:11 UTC 2022
|
Record UNII |
06LU7C9H1V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 862.1715
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
83124-8
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
26879-7
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
83125-5
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
FDA ORPHAN DRUG |
539116
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
NCI_THESAURUS |
C1553
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
WHO-VATC |
QH03AA03
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
NDF-RT |
N0000006165
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
CFR |
21 CFR 862.1710
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
CFR |
21 CFR 520.1284
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
3053-6
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
14930-2
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
WHO-ATC |
H03AA03
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
3055-1
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
NDF-RT |
N0000175946
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
NCI_THESAURUS |
C886
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LIVERTOX |
1000
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
70152-4
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
NDF-RT |
N0000006165
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
35231-0
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
||
|
LOINC |
57899-7
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
06LU7C9H1V
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
1368008
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
57164-27-9
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
SUPERSEDED | |||
|
1585
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
SUB08527MIG
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
DTXSID8023216
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
229-999-3
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
10814
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | RxNorm | ||
|
80203
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
DB00279
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
M6835
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | Merck Index | ||
|
3110
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
C907
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
653
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
06LU7C9H1V
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
18258
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
Liothyronine
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
6893-02-3
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
LIOTHYRONINE
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
CHEMBL1544
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
2634
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
D014284
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
533015
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY | |||
|
7013-53-8
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
SUPERSEDED | |||
|
5920
Created by
admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
SALT/SOLVATE -> PARENT | |||
|
LABELED -> NON-LABELED | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
LABELED -> NON-LABELED | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
The relative response factor is 1.00
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |